Daniel J A Margolis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1539017/publications.pdf

Version: 2024-02-01

107 papers 11,771 citations

34 h-index 97 g-index

109 all docs

109 docs citations

109 times ranked 8119 citing authors

#	Article	IF	CITATIONS
1	PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. European Urology, 2016, 69, 16-40.	0.9	2,290
2	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036
3	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351.	0.9	1,270
4	Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. European Urology, 2016, 69, 41-49.	0.9	454
5	Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 2016, 280, 793-804.	3.6	398
6	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	0.9	383
7	Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. European Urology, 2015, 67, 569-576.	0.9	362
8	Prostate cancer detection with magnetic resonanceâ€ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer, 2016, 122, 884-892.	2.0	346
9	Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. European Urology, 2014, 65, 809-815.	0.9	337
10	Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. Journal of Urology, 2016, 196, 1613-1618.	0.2	305
11	Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. Journal of Urology, 2013, 189, 86-92.	0.2	276
12	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	3.6	207
13	Clinical application of a 3D ultrasound-guided prostate biopsy system. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 334-342.	0.8	205
14	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. Cancer Research, 2014, 74, 4638-4652.	0.4	179
15	Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. Journal of Urology, 2017, 197, 320-326.	0.2	173
16	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
17	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. Journal of Urology, 2020, 203, 706-712.	0.2	152
18	Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4178-4188.	1.8	147

#	Article	IF	Citations
19	Use of MR Imaging to Determine Preservation of the Neurovascular Bundles at Robotic-assisted Laparoscopic Prostatectomy. Radiology, 2012, 262, 874-883.	3.6	124
20	Utilizing timeâ€driven activityâ€based costing to understand the short†and longâ€term costs of treating localized, lowâ€risk prostate cancer. Cancer, 2016, 122, 447-455.	2.0	123
21	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. Journal of Urology, 2014, 192, 1367-1373.	0.2	121
22	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	0.8	107
23	Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 903-911.	0.8	91
24	Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. Journal of Urology, 2016, 196, 68-75.	0.2	88
25	In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2–based Diagnostic Performance for Detection of Prostate Cancer. Radiology, 2017, 283, 130-139.	3.6	76
26	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. American Journal of Roentgenology, 2021, 216, 3-19.	1.0	76
27	Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 632-639.	0.2	69
28	Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 10-20.	2.6	63
29	The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer. Urology, 2014, 83, 369-375.	0.5	60
30	Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. Journal of Urology, 2017, 198, 839-847.	0.2	59
31	The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. European Urology Oncology, 2019, 2, 135-140.	2.6	53
32	Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?. American Journal of Roentgenology, 2017, 209, 1272-1277.	1.0	49
33	Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. Journal of Urology, 2018, 199, 453-458.	0.2	47
34	Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 323-336.	1.9	42
35	Correlation of gleason scores with magnetic resonance diffusion tensor imaging in peripheral zone prostate cancer. Journal of Magnetic Resonance Imaging, 2015, 42, 460-467.	1.9	41
36	Measuring human placental blood flow with multidelay 3D GRASE pseudocontinuous arterial spin labeling at 3T. Journal of Magnetic Resonance Imaging, 2018, 47, 1667-1676.	1.9	37

#	Article	IF	CITATIONS
37	Reducing Artifacts during Arterial Phase of Gadoxetate Disodium–enhanced MR Imaging: Dilution Method versus Reduced Injection Rate. Radiology, 2017, 283, 429-437.	3.6	35
38	Pulmonary Embolism in Hospitalized Patients with COVID-19: A Multicenter Study. Radiology, 2021, 301, E426-E433.	3.6	35
39	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 952-957.	0.8	33
40	A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: Results From a Survey of Specialty Societies. American Journal of Roentgenology, 2018, 210, 101-107.	1.0	33
41	Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. Urology, 2015, 86, 432-438.	0.5	29
42	Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. Radiology, 2017, 284, 109-119.	3.6	29
43	Rapid automated liver quantitative susceptibility mapping. Journal of Magnetic Resonance Imaging, 2019, 50, 725-732.	1.9	27
44	Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Practical Radiation Oncology, 2015, 5, 411-416.	1.1	25
45	Population-based study of the incidence and survival for intraductal carcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 673.e9-673.e14.	0.8	25
46	A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. Investigative Radiology, 2019, 54, 437-447.	3.5	24
47	Deep neural network for water/fat separation: Supervised training, unsupervised training, and no training. Magnetic Resonance in Medicine, 2021, 85, 2263-2277.	1.9	24
48	Magnetic Resonance Imaging Radiomicsâ€Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal <scp>Plâ€RADS</scp> 3 Lesions. Journal of Magnetic Resonance Imaging, 2021, 54, 1466-1473.	1.9	24
49	Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2. PLoS ONE, 2017, 12, e0172127.	1.1	23
50	Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. American Journal of Roentgenology, 2019, 213, 1253-1258.	1.0	18
51	Multivariate analysis of CT imaging, laboratory, and demographical features for prediction of acute kidney injury in COVID-19 patients: a Bi-centric analysis. Abdominal Radiology, 2021, 46, 1651-1658.	1.0	18
52	The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. European Urology Oncology, 2018, 1, 263-267.	2.6	17
53	Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy. Urology, 2020, 135, 117-123.	0.5	17
54	Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. American Journal of Roentgenology, 2020, 214, 1101-1111.	1.0	17

#	Article	IF	CITATIONS
55	Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e9-637.e15.	0.8	17
56	Increasing Utilization of MRI Before Prostate Biopsy in Black and Non-Black Men: An Analysis of the SEER-Medicare Cohort. American Journal of Roentgenology, 2021, 217, 389-394.	1.0	17
57	Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma. Academic Radiology, 2017, 24, 1226-1232.	1.3	15
58	PI-RADS: what is new and how to use it. Abdominal Radiology, 2020, 45, 3951-3960.	1.0	14
59	Multiparametric MRI for Localized Prostate Cancer: Lesion Detection and Staging. BioMed Research International, 2014, 2014, 1-11.	0.9	13
60	3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard. Abdominal Radiology, 2018, 43, 3117-3124.	1.0	13
61	Multiparametric MRI identifies and stratifies prostate cancer lesions: Implications for targeting intraprostatic targets. Brachytherapy, 2014, 13, 292-298.	0.2	12
62	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). Academic Radiology, 2019, 26, 5-14.	1.3	12
63	Vying for Standardization of Bladder Cancer MRI Interpretation and Reporting: VI-RADS. Radiology, 2019, 291, 675-676.	3.6	11
64	International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer. Cancers, 2021, 13, 2627.	1.7	11
65	Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma. Radiology, 2019, 292, 103-109.	3.6	10
66	Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. American Journal of Roentgenology, 2019, 213, 365-370.	1.0	10
67	Developments in MRI-targeted prostate biopsy. Current Opinion in Urology, 2020, 30, 1-8.	0.9	10
68	Comparative Effectiveness and Tolerability of Transperineal MRI-Targeted Prostate Biopsy under Local versus Sedation. Urology, 2021, 155, 33-38.	0.5	10
69	68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. Translational Oncology, 2022, 15, 101242.	1.7	10
70	Prostate Multiparametric Magnetic Resonance Imaging Features Following Partial Gland Cryoablation. Urology, 2020, 138, 98-105.	0.5	9
71	Commentary regarding the inter-reader reproducibility of PI-RADS version 2. Abdominal Radiology, 2016, 41, 907-909.	1.0	8
72	3.0Tesla magnetic resonance angiography (MRA) for comprehensive renal evaluation of living renal donors: pilot study with computerized tomography angiography (CTA) comparison. Clinical Imaging, 2016, 40, 370-377.	0.8	8

#	Article	IF	Citations
73	Clear cell renal cell carcinoma: identifying the gain of chromosome 20 on multiphasic MDCT. Abdominal Radiology, 2016, 41, 2175-2181.	1.0	8
74	Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdominal Radiology, 2017, 42, 346-349.	1.0	8
75	Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. American Journal of Roentgenology, 2019, 212, W122-W131.	1.0	8
76	Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study. Journal of Urology, 2020, 203, 530-536.	0.2	8
77	Pilot study of the diagnostic utility of 89 Zrâ€dfâ€lAB2M and 68 Gaâ€PSMAâ€11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate, 2022, , .	^C 1.2	8
78	Radiologists' preferences regarding content of prostate MRI reports: a survey of the Society of Abdominal Radiology. Abdominal Radiology, 2018, 43, 1807-1812.	1.0	7
79	Prostate MRI with PI-RADS v2.1: initial detection and active surveillance. Abdominal Radiology, 2020, 45, 2133-2142.	1.0	6
80	Racial Variation in Membranous Urethral Length and Postprostatectomy Urinary Function. European Urology Open Science, 2021, 27, 61-64.	0.2	5
81	Predictors of acute deep venous thrombosis in patients hospitalized for COVID-19. Medicine (United) Tj ETQq1 1 (07.84314	rgBT /Ove <mark>rl</mark>
82	Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy. Journal of Urology, 2018, 200, 559-563.	0.2	4
83	Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Disease–Focused Panel. American Journal of Roentgenology, 2021, 216, 952-959.	1.0	4
84	A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. Canadian Urological Association Journal, 2021, 16, .	0.3	4
85	Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2022, 54, 431-437.	1.0	4
86	The Director of Prostate Imaging: advancing care for prostate cancer patients. Abdominal Radiology, 2017, 42, 2358-2362.	1.0	3
87	Prostate heterogeneity correlates with clinical features on multiparametric MRI. Abdominal Radiology, 2021, 46, 5369-5376.	1.0	3
88	Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdominal Radiology, 2018, 43, 2487-2496.	1.0	2
89	A Review of Prostate Biopsy Techniques. Seminars in Roentgenology, 2018, 53, 213-218.	0.2	2
90	Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study. BMJ Surgery, Interventions, and Health Technologies, 2020, 2, e000056.	0.6	2

#	Article	IF	Citations
91	Progression of low- to high-grade prostate cancer: Molecular profiling of tissue obtained by serial targeted biopsy Journal of Clinical Oncology, 2015, 33, 5017-5017.	0.8	2
92	MR-TRUS Fusion Biopsy. Topics in Magnetic Resonance Imaging, 2016, 25, 125-131.	0.7	1
93	Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surgery, Interventions, and Health Technologies, 2019, 1, e000010.	0.6	1
94	Utility of dynamic MRA in the evaluation of male erectile dysfunction. Abdominal Radiology, 2020, 45, 1990-2000.	1.0	1
95	Tissue clearing techniques for threeâ€dimensional optical imaging of intact human prostate and correlations with multiâ€parametric MRI. Prostate, 2021, 81, 521-529.	1.2	1
96	Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. Anticancer Research, 2017, 37, 1237-1242.	0.5	1
97	Predictors of biliary intervention in patients hospitalized for COVID-19. Abdominal Radiology, 2022, 47, 1891.	1.0	1
98	Annual short report of the society of abdominal radiology prostate cancer disease-focused panel. Abdominal Radiology, 2019, 44, 4000-4001.	1.0	0
99	Commentary on "MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis― American Journal of Roentgenology, 2021, 216, 584-584.	1.0	0
100	Letter from the Guest Editor: Prostate Imaging. Seminars in Roentgenology, 2021, 56, 362.	0.2	0
101	Prostate Specific Membrane Antigen (PSMA) Positron-Emission Tomography (PET): A Counterpart to Prostate Magnetic Resonance Imaging (MRI). Seminars in Roentgenology, 2021, 56, 363-365.	0.2	0
102	Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI. Seminars in Roentgenology, 2021, 56, 376-383.	0.2	0
103	Editorial Comment. Journal of Urology, 2021, 206, 612-612.	0.2	0
104	791 RECURRENT HIATAL HERNIA A HIGH PREDICTOR OF PATHOLOGIC REFLUX AND NEED FOR REINTERVENTION. Ecological Management and Restoration, 2021, 34, .	0.2	0
105	Editorial Comment. Journal of Urology, 2022, 207, 92-93.	0.2	0
106	Reply by Authors. Journal of Urology, 2020, 203, 536-536.	0.2	0
107	Innovations in prostate cancer: introductory editorial. British Journal of Radiology, 2022, 95, 20229003.	1.0	0